Semaglutide

GLP-1 Receptor Agonist

31 Amino Acids · MW: 4,113.58 Da

Ask AI About This

Amino Acids

Molecular Weight

4,113.58 Da

Half-life

~7 days

Research Score

4.7

Studies

1240

Storage

N/A

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.

Key Benefits & Mechanisms

Significant weight loss (15-20% body weight)

Improved glycemic control and insulin sensitivity

Reduced cardiovascular risk

Appetite suppression and reduced food cravings

Improved metabolic biomarkers

Potential neuroprotective effects

Reduced systemic inflammation

Research Summary

Semaglutide has the most robust clinical evidence of any peptide in this database. Multiple Phase III trials (STEP, SUSTAIN programs) demonstrate 15-20% body weight reduction. FDA-approved with extensive safety data.

Related Peptides

Tirzepatide

GIP/GLP-1 Dual Receptor Agonist

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.

Metabolic

AOD-9604

Anti-Obesity Drug (Modified GH Fragment)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.

Metabolic

Tesamorelin

Synthetic Growth Hormone Releasing Hormone

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.

Metabolic

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA-c

MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis and exercise physiology. It activates AMPK, improves insulin sensitivity, and mimics the metabolic effects of exercise. Discovered at USC, it represents a new class of mitochondrial signaling peptides.

Metabolic